We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+22.77%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$12.2B
AUM Growth
+$2.02B
Cap. Flow
+$1.08B
Cap. Flow %
8.87%
Top 10 Hldgs %
86.71%
Holding
137
New
4
Increased
21
Reduced
9
Closed
18

Top Buys

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.35B
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$11.4M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$9.33M
4
ASND icon
Ascendis Pharma A/S
ASND
+$8.29M
5
NGNE icon
Neurogene
NGNE
+$6.99M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$106M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$19.5M
3
ARRY
Array Biopharma Inc
ARRY
+$10.6M
4
EXEL icon
Exelixis
EXEL
+$8.13M
5
ARCT icon
Arcturus Therapeutics
ARCT
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.9B
$4.56B 37.31%
34,110,011
+10,610,924
+45% +$1.35B
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$2.87B 23.51%
45,715,556
+3,700
+0% +$231K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$5.08B
$888M 7.26%
25,819,768
– –
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$793M 6.49%
6,544,130
+835
+0% +$108K
GHDX
5
DELISTED
Genomic Health, Inc.
GHDX
$434M 3.55%
13,770,982
+680
+0% +$20.1K
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12.9B
$422M 3.45%
4,806,483
– –
DBVT
7
DBV Technologies
DBVT
$914M
$194M 1.59%
550,956
– –
NGNE icon
8
Neurogene
NGNE
$773M
$182M 1.49%
546,708
+19,903
+4% +$6.99M
ONC
9
BeOne Medicines Ltd
ONC
$42.4B
$134M 1.1%
3,673,175
– –
AKAO
10
DELISTED
Achaogen Inc
AKAO
$116M 0.95%
4,582,382
– –
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.44B
$98.4M 0.81%
11,716,784
+752,840
+7% +$5.24M
AAAP
12
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$88.6M 0.72%
2,221,706
+54,569
+3% +$1.88M
NVTA
13
DELISTED
Invitae Corporation
NVTA
$80.6M 0.66%
7,288,300
– –
AMRN
14
Amarin Corp
AMRN
$298M
$72.5M 0.59%
1,132,823
+24,348
+2% +$1.55M
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$70.3M 0.58%
1,318,341
– –
ACOR
16
DELISTED
Acorda Therapeutics
ACOR
$69.3M 0.57%
27,515
– –
BLCM
17
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$62.1M 0.51%
503,231
+16,666
+3% +$2.18M
CERS icon
18
Cerus
CERS
$566M
$58.1M 0.48%
13,053,275
– –
EXEL icon
19
Exelixis
EXEL
$13.4B
$56.4M 0.46%
2,603,569
-400,000
-13% -$8.13M
HRTX icon
20
Heron Therapeutics
HRTX
$60.4M
$41.8M 0.34%
2,783,569
+400,000
+17% +$5.54M
NBIX icon
21
Neurocrine Biosciences
NBIX
$15.5B
$38.8M 0.32%
895,422
– –
AVXS
22
DELISTED
AveXis, Inc. Common Stock
AVXS
$38M 0.31%
500,000
+184,700
+59% +$11.4M
ASND icon
23
Ascendis Pharma A/S
ASND
$16.6B
$37.8M 0.31%
1,351,463
+328,197
+32% +$8.29M
ARAV
24
DELISTED
Aravive, Inc. Common Stock
ARAV
$35.5M 0.29%
276,766
-43,375
-14% -$4.57M
BLUE
25
DELISTED
bluebird bio
BLUE
$31.9M 0.26%
27,131
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2017 Portfolio in Review

As of Q1 2017, Julian Baker held 137 positions worth $12.2B, up 20% from $10.2B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker deployed $1.08B of net new capital in Q1 2017, opening 4 new positions and adding to 21 existing holdings. Its largest new stake was AnaptysBio: 150,000 shares worth $4.16M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 88% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $10.6M trimmed.

  • Julian Baker's largest Q1 2017 buy was AnaptysBio: 150,000 shares worth $4.16M.
  • Julian Baker added most to Incyte in Q1 2017, an estimated $1.35B increase.
  • Julian Baker's biggest Q1 2017 reduction was Array Biopharma Inc, cutting an estimated $10.6M.
  • Julian Baker fully exited AbbVie in Q1 2017, selling an estimated $106M.
  • Julian Baker's ten largest holdings make up 87% of its $12.2B portfolio in Q1 2017.
  • Julian Baker opened 4 new positions and closed 18 in Q1 2017.
  • Julian Baker's portfolio value rose 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.